JBS
Jbs NV
$11.91
▼ 1.0%Updated Today 3:42 PM ET
JBS at a glance — five pillars scored 0–100 from real filed financials.
Overall: Neutral · 51/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▼ Down 15.0% over the last 12 months
Market Cap
$13.10B
P/E
7.43x
Forward P/E (est.)
6.84x
ROE
20.5%
Revenue Growth
48.5%
EPS Growth
8.6%
Profit Margin
2.0%
FCF Yield
—
Debt / Equity
2.65x
ROIC
11.0%
Interest Coverage
2.48x
Current Ratio
1.6x
Dividend Yield
16.4%
Implied Growth (rev. DCF)
2.5%
Rating Score
51/100
Jbs NV (JBS) is a large-cap company in the Food Products industry, part of the Consumer Staples sector of the S&P 500, with a market value around $13.10B.
In its latest reported year it generated about $86.18B in revenue and $2.02B in net profit.
Our model rates JBS Neutral (51/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what JBS's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. JBS trades near $11.91, below its 50-day average ($13.50) and 200-day average ($14.62). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 41 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. JBS's is $0.35 (~2.9% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month JBS found buyers near $11.49 (support) and sellers near $12.71 (resistance); its 52-week range is $11.49–$18.65. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.2× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
2Y CAGR
8.7%
Revenue moved from $72.92B in 2023 to $86.18B in 2025, a 8.7% compound annual growth rate. The most recent year grew a strong 48.5% year over year. Consistent top-line growth is one sign of healthy demand.
Gross Margin
13.1%
Operating Margin
4.8%
Net Margin
2.3%
ROE
20.5%
Jbs NV keeps about 2.0% of each sales dollar as net profit, with a 13.1% gross margin and 4.8% operating margin. Return on equity is 20.5% and return on invested capital about 11.0%. Thin margins leave less cushion if costs rise.
Total Debt
$20.26B
Net Debt
$15.69B
Net Debt / EBITDA
3.77x
Debt / Equity
2.65x
Leverage: debt-to-equity is 2.6x, and operating profit covers interest about 2.5x, with a current ratio of 1.6x. That is elevated leverage, which raises risk if earnings or rates move against it. It carries roughly $20.26B of total debt against $4.57B of cash.
Operating CF
$2.93B
Free Cash Flow
$832.68M
FCF Margin
1.0%
In the latest year Jbs NV produced about $2.93B of operating cash flow and $832.68M of free cash flow after capital spending. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
Can the payout survive a bad year? Scored from filed cash flow, earnings coverage, and the raise/cut record.
Coverage is weak, the payout was cut recently, or it's being financed rather than earned — treat the current yield as fragile.
Dividend yield
16.4%
Total paid (latest FY)
$1.57B
History on record
3 years
dividend uses 189% of free cash flow
78% of net income paid out
total dividends increased 2 years in a row
no cuts in the last 3 years on record
Coverage uses the latest fiscal year as filed with the SEC; the streak counts total dollars paid (per-share figures can carry split artifacts). Educational information, not income advice.
P/E
7.43x
P/S
0.15x
P/B
1.75x
EV / EBITDA
4.45x
JBS trades at 7.4x trailing earnings (about 6.8x on estimated forward earnings), 0.2x sales, and 1.8x book value. Reverse-engineering today's price implies the market expects roughly 2.5% long-term free-cash-flow growth. That is an undemanding multiple — potentially cheap if the business is stable.
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
DCF fair value / share
$364.74
Current price
$11.91
Starting FCF (latest 10-K)
$832.68M
Growth, years 1–5
20.0%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Where JBS sits versus its Consumer Staples sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 48 Consumer Staples companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How JBS stacks up against its Consumer Staples peers — valuation, profitability, and growth versus the sector median.
In the Consumer Staples sector (74 S&P 500 companies), JBS ranks #20 of 74 by our overall rating. It trades at a discount versus the sector on earnings (7.4x P/E vs. 22.2x median) with a higher return on equity (20.5% vs. 18.1%) and faster revenue growth (48.5% vs. 3.4%).
P/E vs sector
7.4x
median 22.2x
ROE vs sector
20.5%
median 18.1%
Growth vs sector
48.5%
median 3.4%
Sector rank
#20
of 74 by rating
Peers are the closest Consumer Staples companies by sub-industry and size. Sector median is across all 74 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $11.91 today · expected CAGR 45% – 59%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $124.97B | $181.20B | $262.74B | $380.98B | $552.42B |
| Net income | $3.75B | $5.44B | $7.88B | $11.43B | $16.57B |
| EPS | $3.41 | $4.94 | $7.17 | $10.39 | $15.07 |
| Share price (low) | $17.04 | $24.71 | $35.83 | $51.96 | $75.34 |
| Share price (high) | $27.27 | $39.54 | $57.33 | $83.13 | $120.54 |
| CAGR (low–high) | 43% / 129% | 44% / 82% | 44% / 69% | 45% / 63% | 45% / 59% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for JBS:
- Revenue is growing 48.5% a year, a sign of real demand.
- Strong return on equity (20.5%) shows capital is put to work well.
- Pays a 16.4% dividend on top of any price gains.
The case against JBS:
- Thin net margins (2.0%) leave little room for error.
- Elevated leverage (debt/equity 2.6x) adds financial risk.
- Interest coverage is thin (2.5x), so debt costs bite.
Balance-sheet risk — debt/equity of 2.6x magnifies the impact of higher rates or weaker earnings.
Margin risk — thin profitability (2.0%) is vulnerable to cost or pricing pressure.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Jbs NV is a large-cap consumer staples business still growing nicely, with modest profitability, and a heavier debt load to watch. It trades at 7.4x earnings, which our model scores Neutral (51/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 17 Wall Street analysts covering JBS recommend (July 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Analysts have turned more cautious over the last three months (-6 pts of buy ratings).
Latest SEC Filings
JBS's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
In the Idea Lab
JBS — frequently asked questions
Is JBS a good stock to buy?
We don't give buy or sell advice. Our model rates Jbs NV Neutral (51/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is JBS's rating on The Stocks School?
Jbs NV currently scores 51/100 (Neutral) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does JBS's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Jbs NV's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for JBS calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this JBS analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell JBS. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.